Skip to main content

Table 2 SCORAD index at the various times of stage 1 in groups A and B, and in stage 2 for groups A (placebo), B (treatment), placebo/placebo (AA) and treatment/treatment (BB) groups

From: Long-term treatment with low-dose medicine in chronic childhood eczema: a double-blind two-stage randomized control trial

  N Mean SD± % of change vs T0 p value
FIRST STAGE
 Group A placebo
  T0 40 13.93 8.28   
  T3 37 11.00 11.08 21.0 0.2
  T6 34 10.15 11.71 27.1 0.12
  T8 33 8.15 4.15 41.5 0.001
  T14FU 32 6.53 3.21 53.2 0.0001
  total 177 10.18 8.83   
 Group B treatment
  T0 40 14.71 7.65   
  T3 35 9.74 10.25 33.8 0.0218
  T6 35 8.00 10.45 45.6 0.0026
  T8 33 6.79 4.08 53.8 0.001
  T14FU 33 5.30 3.82 63.9 0.0001
  total 177 9.17 8.47   
SECOND STAGE
 Group AA placebo/ placebo
  T0 22 6.23 3.13   
  T8 22 5.86 6.32 5.9 0.81
  T9FU 22 4.64 8.30 25.5 0.41
 Group BB treatment/treatment
  T0 27 5.22 3.75   
  T8 27 5.07 3.05 2.9 0.87
  T9FU 27 3.52 2.59 32.6 0.058